GlycoVaxyn AG, a privately-owned Swiss biotechnology company, has raised CHF 25 million in a Series B financing to support the clinical development of its lead vaccine candidate for intestinal infections.
H. Lundbeck A/S of Denmark has reported a record DKK 11.3 billion in revenue for 2008 following the double-digit growth of its three marketed drugs for neurological disorders, Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline).
Researchers from the UK and Canada have reported a method for reprogramming human skin cells to act like embryonic stem cells without the use of viral vectors.
Stem Cell Sciences Plc, a UK stem-cell engineering company that has been seeking a buyer for some months, has agreed to sell its operating assets and substantially all of its intellectual property to StemCells Inc of the US in a share and debt transaction valued at $4.85 million.
Index Ventures, the Geneva-based venture capital company, has closed its fifth fund devoted to early-stage and seed investment in companies involved in advanced technologies. The fund, Index Ventures V, has assets of €350 million.
IP Group Plc, which commercialises intellectual property from UK research institutions, reported a 25% decline in the estimated market value of its holdings in life-science therapeutic companies in 2008.
When is information about a pharmaceutical product neutral, and when does it cross the line to become promotional? This question is stimulating a debate in Brussels about a new legislative proposal that would give pharmaceutical companies more opportunity to communicate directly with consumers about their prescription-only medicines.
Intercell AG expects to see strong revenue growth in 2009 following the launch of its first-ever product on the market, a vaccine to prevent Japanese Encephalitis.
Epistem Plc, a UK-listed biotechnology company, has signed a multi-million dollar research and development agreement with Novartis to identify new drug targets and therapeutics across a range of disease areas.
The Belgian-listed biotechnology company, ThromboGenics NV, has received a grant of up to €3.2 million to support the development of an antibody that would increase the platelet count of cancer patients who have had chemotherapy.